Shilpa Medicare’s arm gets marketing authorization permission for Adalimumab injection

30 Jun 2023 Evaluate

Shilpa Medicare’s wholly owned subsidiary -- Shilpa Biologicals (SBPL) has received the marketing authorization permission for its Adalimumab 40 mg/0.4mL injection in prefilled syringe (PFS), a biosimilar of adalimumab higher concentration formulation (100mg/mL) in India. This is used for the treatment of Rheumatoid Arthritis (moderate to severe active RA & severe active and progressive RA) for which the phase 3 clinical trial has been successfully completed in Q3 2022. This formulation will contribute to increased patient comfort based on reduced injection volume.  

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

276.40 -2.15 (-0.77%)
21-Jan-2026 14:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1614.30
Dr. Reddys Lab 1162.35
Cipla 1370.55
Zydus Lifesciences 872.55
Lupin 2142.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×